PD-1/PD-L1 Inhibitors and Anti-angiogenic Therapy Combined With/Without TACE/HAIC in Patients With BCLC B/C Hepatocellular Carcinoma Beyond Up-to-7

NCT06423144 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

PROCEDURE: TACE/HAIC
DRUG: PD-1/PD-L1 inhibits and anti-angiogenic agents

Sponsor

Shanghai Zhongshan Hospital